Altimmune

New York, USA, June 27, 2023 (GLOBE NEWSWIRE) -- Obesity Market to Witness a Robust Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Amgen, Novo Nordisk, Eli Lilly and…

GAITHERSBURG, Md., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of first dosing of all…

All 3 pemvidutide dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved the primary endpoint of relative and absolute reductions in liver fat, with a 68.5% relative reduction in liver fat content…

GAITHERSBURG, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2022…

GAITHERSBURG, Md., April 01, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in…

GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical…

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management…